Wayne Winegarden
Commentary
There Are High Costs From Implementing Drug Price Controls
Once wide coercive powers are given to government agencies…such powers cannot be effectively controlled. F.A. Hayek As part of the chorus calling for drug price controls, the New York Times editorial page has claimed that “Americans will need to accept a trade-off that other advanced nations long since come around to: Slightly ...
Business & Economics
NEW STUDY finds Overregulation Hurts Immigrant and Low-Income Entrepreneurs Trying to Achieve the American Dream
A new study released today by the nonpartisan Pacific Research Institute finds that government has erected barriers to opportunity that make it very difficult for immigrant and low-income entrepreneurs to lift themselves out of poverty and climb the economic ladder. Click here to download “Entrepreneurship as a Pathway to the ...
Commentary
We Need A Cure For The Arrogance Of Drug Price Control Advocates
“Three hundred forty-five billion dollars in savings versus the cost of eight to 15 fewer drugs over 10 years, I frankly think it’s worth it.” Rep. Darren Soto (D-FL), hearing before the House Energy and Commerce Committee In the above quote, Representative Soto is defending H.R. 3, the drug price control ...
Commentary
Medicare’s Denial Of Coverage To Kidney Patients Could Be Just The Beginning
In September 2018, the Centers for Medicare & Medicaid Services (CMS) sent an email announcing that it would no longer cover Auryxia®. Auryxia® is an FDA approved medicine that treats iron deficiency anemia (anemia) for patients with chronic kidney disease (CKD) but who are not on dialysis. People with CKD ...
Climate Change
Policies Should Address Global Climate Change By Incenting Innovation
Amidst all of the rhetoric and dire predictions surrounding global climate change, it is easy to lose one’s perspective. But, we will not successfully minimize the risks created by global climate change without perspective. Fundamental to this perspective, U.S. greenhouse gas (GHG) emissions have been declining for more than a ...
Business & Economics
NEW ISSUE BRIEF: Biosimilars Study Shows Massive State and Taxpayer Savings Possible by Expanding Biosimilars Market
Biosimilars have the opportunity to bring significant savings to state Medicaid programs and consumers with commercial insurance according to a new study released today by Pacific Research Institute. “Every state would experience significant savings in the state Medicaid programs from expanding the use of biosimilars compared to the more expensive ...
Business & Economics
Why Is Sen. Schumer Suddenly Decrying High Tax Rates?
Senate Minority Leader Charles Schumer, D-New York, recently stood in front of a home in a beautiful neighborhood in White Plains, NY, to decry — of all things — the area’s high local tax burden. “We all know that one of the biggest burdens to live in this beautiful place ...
California
‘Pay-for-Delay’ Generic Drug Bill Will Harm Californians
San Diegans and all Californians will pay a high price should a bill introduced by Assemblyman Jim Wood, a Democrat from Santa Rosa, become law. Proponents claim the bill is necessary to rein in anti-competitive practices by the pharmaceutical industry, but in reality, it will delay generic entry and raise the ...
Commentary
More Competition Will Improve Drug Affordability
Making medicines more affordable for patients promises to be a top policy priority for Congress when it returns from its August recess. Achieving this goal does not require new, elaborate, government programs or regulations. It requires reforms that will empower biosimilars to more effectively compete against originator biologics. To see ...
Business & Economics
Sacramento, not D.C., is responsible for California’s unaffordable tax burden
Last fall, Democratic congressional candidates successfully painted the 2017 federal Tax Cuts and Jobs Act as a tax increase on hard working Californians to pick-up even more congressional seats. Congress, they charged, raised the tax burden of many Californians by, among other things, capping the State and Local Tax, or ...
There Are High Costs From Implementing Drug Price Controls
Once wide coercive powers are given to government agencies…such powers cannot be effectively controlled. F.A. Hayek As part of the chorus calling for drug price controls, the New York Times editorial page has claimed that “Americans will need to accept a trade-off that other advanced nations long since come around to: Slightly ...
NEW STUDY finds Overregulation Hurts Immigrant and Low-Income Entrepreneurs Trying to Achieve the American Dream
A new study released today by the nonpartisan Pacific Research Institute finds that government has erected barriers to opportunity that make it very difficult for immigrant and low-income entrepreneurs to lift themselves out of poverty and climb the economic ladder. Click here to download “Entrepreneurship as a Pathway to the ...
We Need A Cure For The Arrogance Of Drug Price Control Advocates
“Three hundred forty-five billion dollars in savings versus the cost of eight to 15 fewer drugs over 10 years, I frankly think it’s worth it.” Rep. Darren Soto (D-FL), hearing before the House Energy and Commerce Committee In the above quote, Representative Soto is defending H.R. 3, the drug price control ...
Medicare’s Denial Of Coverage To Kidney Patients Could Be Just The Beginning
In September 2018, the Centers for Medicare & Medicaid Services (CMS) sent an email announcing that it would no longer cover Auryxia®. Auryxia® is an FDA approved medicine that treats iron deficiency anemia (anemia) for patients with chronic kidney disease (CKD) but who are not on dialysis. People with CKD ...
Policies Should Address Global Climate Change By Incenting Innovation
Amidst all of the rhetoric and dire predictions surrounding global climate change, it is easy to lose one’s perspective. But, we will not successfully minimize the risks created by global climate change without perspective. Fundamental to this perspective, U.S. greenhouse gas (GHG) emissions have been declining for more than a ...
NEW ISSUE BRIEF: Biosimilars Study Shows Massive State and Taxpayer Savings Possible by Expanding Biosimilars Market
Biosimilars have the opportunity to bring significant savings to state Medicaid programs and consumers with commercial insurance according to a new study released today by Pacific Research Institute. “Every state would experience significant savings in the state Medicaid programs from expanding the use of biosimilars compared to the more expensive ...
Why Is Sen. Schumer Suddenly Decrying High Tax Rates?
Senate Minority Leader Charles Schumer, D-New York, recently stood in front of a home in a beautiful neighborhood in White Plains, NY, to decry — of all things — the area’s high local tax burden. “We all know that one of the biggest burdens to live in this beautiful place ...
‘Pay-for-Delay’ Generic Drug Bill Will Harm Californians
San Diegans and all Californians will pay a high price should a bill introduced by Assemblyman Jim Wood, a Democrat from Santa Rosa, become law. Proponents claim the bill is necessary to rein in anti-competitive practices by the pharmaceutical industry, but in reality, it will delay generic entry and raise the ...
More Competition Will Improve Drug Affordability
Making medicines more affordable for patients promises to be a top policy priority for Congress when it returns from its August recess. Achieving this goal does not require new, elaborate, government programs or regulations. It requires reforms that will empower biosimilars to more effectively compete against originator biologics. To see ...
Sacramento, not D.C., is responsible for California’s unaffordable tax burden
Last fall, Democratic congressional candidates successfully painted the 2017 federal Tax Cuts and Jobs Act as a tax increase on hard working Californians to pick-up even more congressional seats. Congress, they charged, raised the tax burden of many Californians by, among other things, capping the State and Local Tax, or ...
